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To establish a safer and more effective vaccine against pneumococcal respiratory infections, current knowledge regarding the
antigens common among pneumococcal strains and improvements to the system for delivering these antigens across the muco-
sal barrier must be integrated. We developed a pneumococcal vaccine that combines the advantages of pneumococcal surface
protein A (PspA) with a nontoxic intranasal vaccine delivery system based on a nanometer-sized hydrogel (nanogel) consisting
of a cationic cholesteryl group-bearing pullulan (cCHP). The efficacy of the nanogel-based PspA nasal vaccine (cCHP-PspA) was
tested in murine pneumococcal airway infection models. Intranasal vaccination with cCHP-PspA provided protective immunity
against lethal challenge with Streptococcus pneumoniae Xen10, reduced colonization and invasion by bacteria in the upper and
lower respiratory tracts, and induced systemic and nasal mucosal Th17 responses, high levels of PspA-specific serum immuno-
globulin G (IgG), and nasal and bronchial IgA antibody responses. Moreover, there was no sign of PspA delivery by nanogel to
either the olfactory bulbs or the central nervous system after intranasal administration. These results demonstrate the effective-
ness and safety of the nanogel-based PspA nasal vaccine system as a universal mucosal vaccine against pneumococcal respiratory
infection.
The use of polysaccharide-based injectable multivalent pneu-mococcal conjugate vaccines (PCV7, -10, and -13) has dimin-
ished the number of fatal infections due to pneumococci express-
ing the particular polysaccharides present in the vaccine (1–3).
However, Streptococcus pneumoniae remains a problematic patho-
gen (4, 5) because of the large number of different capsular poly-
saccharides associated with virulent disease in humans. In partic-
ular, nonvaccine strains are emerging pathogens that result in
morbidity and mortality due to pneumococcal diseases, including
pneumonia and meningitis (6–8).
Clinical demand to overcome these problems has prompted
the preclinical development of universal serotype-independent
pneumococcal vaccines that are based on a surface protein com-
mon to all strains. Pneumococcal surface protein A (PspA), a
pneumococcal virulence factor (9–13), is genetically variable
(14) but highly cross-reactive (9, 10). PspA is commonly ex-
pressed by all capsular serotypes of S. pneumoniae (15) and is
classified into 3 families (family 1, clades 1 and 2; family 2,
clades 3 through 5; and family 3, clade 6) according to sequence
similarities (14). Given that parenteral immunization with
PspA induces cross-reactive neutralizing immune responses in
mice (16–18) and humans (19), using PspA as a serotype-inde-
pendent common antigen for the development of pneumococ-
cal vaccines seems to be an ideal strategy.
Pneumococcal infection is generally preceded by colonization
of the upper airway (20, 21). Nasal carriage of pneumococci is the
primary source for spread of the infection among humans (22,
23). Therefore, an optimal vaccine strategy to prevent and control
the spread of pneumococcal disease would induce protective im-
munity against both colonization and invasive disease. Several
studies have confirmed the efficacy of PspA as a nasal vaccine
antigen by coadministering PspA with a mucosal adjuvant such as
cholera toxin (CT) or cholera toxin subunit B (CTB) to mice (24–
26). The mice subsequently mount antigen-specific immune re-
sponses in not only the systemic compartment but also the respi-
ratory mucosal compartment (24, 25, 27), where bacterial
colonization occurs (20). PspA-specific secretory immunoglobu-
lin A (sIgA) antibodies induced by intranasal immunization with
PspA and an adjuvant (i.e., a plasmid expressing Flt3 ligand
cDNA) provide protection against pneumococcal colonization
(28). In addition, studies in mice have revealed that this protection
is mediated by antigen-specific interleukin 17A (IL-17A)-secret-
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ing CD4 T cells induced by intranasal immunization with pneu-
mococcal whole-cell antigen (29, 30).
Therefore, the intranasal vaccination route is an improved
route for preventing colonization of the nasal cavity by pneumo-
cocci. A leading obstacle to the practical use of nasal vaccine with
a protein-based pneumococcal antigen is the need to coadminis-
ter a toxin-based mucosal adjuvant (e.g., CT) for effective induc-
tion of antigen-specific immune responses (31, 32). However, the
use of such toxin-based adjuvants is undesirable in humans, as it
carries the concern that the toxin may reach the central nervous
system (CNS) or redirect the vaccine antigen into the CNS
through the olfactory nerve in the nasal cavity (33, 34). To bypass
these concerns, we recently developed a nasal vaccine delivery
system based on a non-toxin-based mucosal antigen carrier, a
cationic cholesteryl pullulan (cCHP) nanogel (35).
Here we show the efficacy of a nanogel-based nasal pneumo-
coccal vaccine in which PspA is incorporated into a cCHP nanogel
(cCHP-PspA). We also characterized the cCHP-PspA-induced
PspA-specific Th17 and antibody responses against S. pneu-
moniae. Mice immunized with nasal cCHP-PspA were protected
from lethal challenge with S. pneumoniae and had fewer pneumo-
cocci on their respiratory mucosae. These results suggest that a
nontoxic nasal vaccine comprising nanogel-based PspA offers a
practical and effective strategy against pneumococcal infection by
preventing both nasal colonization and invasive diseases.
MATERIALS AND METHODS
Mice. Female BALB/c mice (aged 6 to 7 weeks) were purchased from SLC
(Shizuoka, Japan). All of the mice were housed with ad libitum food and
water on a standard 12-h–12-h light-dark cycle. All experiments were
performed in accordance with the guidelines provided by the Animal Care
and Use committees of the University of Tokyo and were approved by the
Animal Committee of the Institute of Medical Science of the University of
Tokyo.
Recombinant PspA. Recombinant PspA of S. pneumoniae Rx1, which
belongs to PspA family 1, clade 2 (14), was prepared as described previ-
ously, with slight modifications (26). Briefly, a plasmid encoding PspA/
Rx1 (pUAB055; amino acids 1 through 302) (GenBank accession no.
M74122) was used to transform Escherichia coli BL21(DE3) cells. This
construct contains amino acids 1 through 302 of the PspA protein from
strain Rx1 plus a 6His tag at the C terminus (26). The sonicated cell
supernatant was loaded onto a DEAE-Sepharose column (BD Healthcare,
Piscataway, NJ) and a nickel affinity column (Qiagen, Valencia, CA). This
was followed by gel filtration on a Sephadex G-100 column (BD Health-
care).
Preparation of cCHP-recombinant PspA complex for intranasal
vaccination. A cCHP nanogel (size, 40 nm) generated from a cationic
cholesteryl group-bearing pullulan was used for all experiments. The
cCHP-PspA complex for each immunization was prepared by mixing 7.5
g PspA with cCHP at a 3:1 molecular ratio (volume, 18 l per mouse)
and incubating the mixture for 1 h at 45°C. Before the complex was used
in in vivo studies, the fluorescence resonance energy transfer (FRET) of
fluorescein isothiocyanate (FITC)-PspA and a tetramethyl rhodamine
isothiocyanate (TRITC)-cCHP nanogel was measured with a fluorescence
spectrometer (model FP-6500; Jasco, Easton, MD) as described previ-
ously (37). FRET analyses confirmed that the cCHP nanogel appropri-
ately formed nanoparticles after the incorporation of PspA (see Fig. S1 in
the supplemental material). Dynamic light scattering analysis showed that
the cCHP nanogel maintained the same nanoscale size (32.8  0.2 nm)
even after the incorporation of PspA. Lipopolysaccharide (LPS) contam-
ination of purified PspA and cCHP (10 endotoxin units/mg protein)
was measured with a Limulus test (Wako, Osaka, Japan).
Immunization. Once weekly for 3 consecutive weeks, female BALB/c
mice were immunized intranasally with cCHP-PspA, PspA plus CT (1 g;
List Biological Laboratory, Campbell, CA), PspA alone, or phosphate-
buffered saline (PBS) only. Some experiments included an irrelevant an-
tigen as a control; in these studies, mice were immunized intranasally with
a complex of cCHP nanogel and a recombinant nontoxic receptor-bind-
ing fragment of Clostridium botulinum type A neurotoxin subunit antigen
Hc (cCHP-BoHc/A) (35). Serum, nasal wash fluid (NW), and bronchoal-
veolar lavage fluid (BALF) samples were harvested 1 week after the last
immunization. For NWs, 200 l sterile PBS was flushed through the pos-
terior choanae (38). BALF was harvested by instilling 1 ml of sterile PBS
through a blunt needle placed in the trachea (38).
Bacterial strain. We used the kanamycin-resistant pneumococcal
strain S. pneumoniae Xen10 (Caliper Life Sciences, MA), derived from the
wild-type strain A66.1, which expresses PspA of family 1, clades 1 and 2
(39). S. pneumoniae Xen10 carries a stable copy of the modified Photorh-
abdus luminescens lux operon at a single integration site on the bacterial
chromosome (40). The virulence of S. pneumoniae Xen10 is comparable
to that of the parent strain (40, 41). For challenge studies, S. pneumoniae
3JYP3670, which expresses PspA of family 2, clade 4, was used (10). All of
the S. pneumoniae strains were grown in brain heart infusion (BHI) broth
at 37°C in 5% CO2.
Pneumococcal infection model. To evaluate the efficacy of intranasal
vaccination with cCHP-PspA, mice were challenged 1 week after the last
immunization. The cell densities of exponentially growing S. pneumoniae
Xen10 cultured at 37°C in BHI broth were estimated from the optical
density at 600 nm (OD600); cells were pelleted and then diluted with PBS.
Lethal (2  105 CFU) and sublethal (2  104 CFU) challenge doses diluted
in 50 l sterile PBS were administered intranasally to isoflurane-anesthe-
tized mice. Mice were restrained vertically for 5 min to ensure inhalation
of the organisms into the trachea. In addition, mice were inoculated in-
tranasally with a lethal challenge dose (5  104 CFU) of strain 3JYP3670 in
the same way as that for strain Xen10. Nasal passages and lung tissues were
homogenized in 500 l sterile PBS for 1 min, and the numbers of bacterial
colonies were determined by plating samples on LB agar plates containing
kanamycin (200 l/ml).
In vivo imaging of immunized and challenged mice. Biolumines-
cence of bacteria was monitored for 1 min 24, 48, and 72 h after lethal
challenge by using an Ivis charge-coupled device (CCD) camera (Xeno-
gen, Alameda, CA). Total photon emission from the entire thorax of each
mouse was quantified by using the LivingImage software package (Xeno-
gen). The results are provided as numbers of photons/s/cm2/sr.
Antibody titer and subclass analysis. Antibody titers were deter-
mined by using enzyme-linked immunosorbent assay (ELISA) as de-
scribed previously, with slight modifications (25). In brief, samples (2-
fold serial dilutions) were loaded into individual wells, and the plate was
coated with 1 g/ml recombinant PspA and incubated. Goat anti-mouse
IgA, IgG, IgG1, IgG2a, IgG2b, IgG3, and IgM (dilution factor, 1:4,000)
conjugated with horseradish peroxidase were used as secondary antibod-
ies. Reactions were visualized by using the TMB microwell peroxidase
substrate system (XPL, Gaithersburg, MD). The endpoint titer is ex-
pressed as the reciprocal log2 of the last dilution that gave an OD450 that
was 0.1 unit greater than that of the negative control.
PspA-specific CD4 T cell responses. By using anti-CD4 microbeads
(Miltenyi Biotec, Sunnyvale, CA) according to the manufacturer’s in-
structions, CD4 T cells were isolated from the spleens and cervical lymph
nodes (CLNs) of mice intranasally immunized with cCHP-PspA, PspA
alone, or PBS only. The purified CD4 T cells were resuspended at 1  106
cells/ml in RPMI 1640 (Cellgro, Mediatech, Washington, DC) supple-
mented with 10 mM HEPES, 50 M 2-mercaptoethanol, 100 U/ml pen-
icillin, 100 l/ml streptomycin, and 10% fetal calf serum and then cocul-
tured with irradiated (2,000 rad) splenic antigen-presenting cells (2  106
cells/ml) from naïve BALB/c mice for 5 days at 37°C in 5% CO2 in the
presence of 1 g/ml PspA. Cytokine levels in CD4 T cell culture super-
natants were determined by using cytokine-specific DuoSet ELISA kits
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(R&D Systems, Minneapolis, MN) according to the manufacturer’s in-
structions.
Radioisotope counting assay. To trace the distribution of PspA after
intranasal immunization, PspA was labeled with indium chloride (Nihon
Medi-Physics, Tokyo, Japan) anhydride (Dojindo, Kumamoto, Japan) via
N-terminal and ε-Lys amino groups, using diethylenetriaminepentaacetic
acid as described previously (42). 111In-labeled PspA was administered
alone or as a complex with cCHP nanogel. The radioisotope counts in the
nasal passage, olfactory bulbs, and brain 10 min and 1, 6, 12, 24, and 48 h
after instillation were estimated with a -counter (Wizard model 1480;
PerkinElmer, Waltham, MA). The results are provided as standardized
uptake values (SUVs), calculated as radioisotope counts (cpm) per gram
of tissue divided by the ratio of the injected dose (1  106 cpm) to body
weight (in grams).
Flow cytometric analysis. Mice were immunized intranasally with
FITC-PspA in cCHP nanogel, FITC-PspA alone, or PBS only; 6 h later,
mononuclear cells were prepared from the nasal passages of each group by
mechanical dissociation through 70-m nylon mesh, as described previ-
ously (38, 43). Isolated cells were stained with phycoerythrin (PE)-Cy7-
conjugated anti-CD11c (BD Bioscience) and analyzed by flow cytometry.
The percentage of PspA cells in the CD11c fractions was calculated for
each experimental group.
Data analysis. Data are expressed as means  standard deviations
(SD). Statistical analysis for most comparisons among groups was per-
formed with Tukey’s t test; differences were considered statistically signif-
icant when the P value was 0.05. For survival data, the Fisher exact test
was used to compare the numbers of alive versus dead mice in the cCHP-
PspA, PspA-CT, and PBS-only groups with those in the PspA-only group.
RESULTS
Intranasal vaccination with cCHP-PspA induces protective im-
munity against lethal challenge with S. pneumoniae. To evaluate
whether intranasal cCHP-PspA vaccination induces protective
immunity against pneumococcal challenge, we vaccinated mice
with cCHP-PspA, PspA-CT, PspA alone, or PBS only. One week
after the last immunization, we lethally challenged vaccinated
mice with the virulent strain S. pneumoniae Xen10 (2  105 CFU),
which is S. pneumoniae A66.1 rendered bioluminescent by the
integration of a modified lux operon into its chromosome (40).
The PspA expression level of strain Xen10 was confirmed to be
comparable to that of the parent strain (see Fig. S2 in the supple-
mental material). We then evaluated survival rates after lethal
challenge over a 2-week period. The survival rate of the cCHP-
PspA-vaccinated group was 100%, as was that for PspA-CT-vac-
cinated mice (Fig. 1). In contrast, most of the mice intranasally
immunized with PspA alone (survival rate, 0%) or with PBS (20%
survival) died within 8 days of challenge with S. pneumoniae
Xen10 (Fig. 1). The survival rates of the groups immunized with
cCHP-PspA or PspA-CT were higher and were statistically signif-
icant compared to that of the group immunized with PspA alone
(P  0.01). The results from the PspA-only and PBS-only groups
did not differ (P  0.05). In addition, immunization with the
irrelevant antigen BoHc/A incorporated into cCHP (cCHP-
BoHc/A) (35) did not protect mice from challenge with S. pneu-
moniae Xen10 (see Fig. S3). Because PspA family 2 (clades 3
through 5) and family 1 (clades 1 and 2) constitute 94 to 99% of
clinical isolates of pneumococci (14, 44–49), we also challenged
mice with the strain 3JYP3670, which expresses PspA belonging to
clade 4 of family 2 (10). Unlike mice inoculated with cCHP-
BoHc/A, PspA alone, or PBS only, mice nasally immunized with
cCHP-PspA were protected from lethal challenge with 3JYP3670
(PspA of clade 4) (10), as was the case with Xen10 expressing PspA
of clades 1 and 2 (see Fig. S4).
Intranasal vaccination with cCHP-PspA enhances bacterial
clearance from BALF and the lung. To assess whether intranasal
immunization with cCHP-PspA prevented pulmonary infection
with pneumococci, we performed in vivo bioluminescence imag-
ing of S. pneumoniae Xen10 after lethal challenge (2  105 CFU) of
mice intranasally vaccinated with cCHP-PspA, PspA alone, or
PBS. The lungs of mice immunized with PspA alone or with PBS
only (control group) showed high-intensity photon signals in a
pattern consistent with that of full-blown lung infection (Fig. 2A).
In contrast, the lungs of mice immunized with cCHP-PspA lacked
bioluminescence, indicating the absence of pulmonary infection.
Forty-eight and 72 h after infection, photon counts of the cCHP-
PspA-vaccinated group were significantly lower than those of the
other two groups (Fig. 2B).
To investigate whether intranasal immunization with cCHP-
PspA hastened bacterial clearance from the lung, we counted the
bacteria in the BALF and lung tissues of mice intranasally vacci-
nated with cCHP-PspA, PspA alone, or PBS and sublethally chal-
lenged with S. pneumoniae Xen10 (2  104 CFU). Three hours
after challenge, bacterial numbers in BALF (Fig. 2C) and lung
tissue (Fig. 2D) did not differ among the three vaccination groups.
However, 24 h after challenge, the bacterial counts in the BALF
and lung homogenates from the cCHP-PspA-vaccinated groups
were significantly lower (about 100-fold) than those for the mice
immunized with PspA alone or PBS only (Fig. 2C and D).
Intranasal vaccination with cCHP-PspA reduces bacterial
colonization in the nasal cavity. We next examined whether in-
tranasal cCHP-PspA immunization affected nasal carriage of
pneumococci in mice challenged with S. pneumoniae Xen10.
Three days after challenge, bacterial numbers in NWs (Fig. 3A)
and nasal passages (Fig. 3B) of mice immunized with the cCHP-
PspA nasal vaccine were decreased significantly (approximately
100-fold) compared to those for the two control groups.
Intranasal vaccination with cCHP-PspA induces strong
Th17 and Th2 responses. We then examined the type of immune
FIG 1 Intranasal vaccination with cCHP-PspA induced protective immunity
against pneumococci. One week after the final immunization, mice were chal-
lenged with S. pneumoniae Xen10 (2  105 CFU/mouse), and survival was
monitored. Data are representative of three independent experiments, and
each group consisted of 5 mice. P values were calculated by using the Fisher
exact test to compare the numbers of alive versus dead mice in each group with
the result obtained for the PspA-only group. **, P  0.01 compared with the
group immunized with PspA alone. Abbreviations: cCHP, cationic cholesteryl
group-bearing pullulan; CT, cholera toxin; PspA, pneumococcal surface pro-
tein A.
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responses elicited by intranasal cCHP-PspA vaccination. Com-
pared with PspA alone or PBS, cCHP-PspA induced higher levels
of IL-17 in CD4 T cells from the spleen, CLNs, and nasal passages
(Fig. 4A). The cCHP-PspA-vaccinated group produced high levels
of IL-4 and IL-13, the hallmark cytokines of a Th2-type immune
response, but only scant amounts of gamma interferon (Fig. 4B to
D). These results show the potential of a cCHP-PspA nasal vaccine
as an advanced pneumococcal vaccine that can induce a Th17
response together with a Th2-type immune response.
Intranasal vaccination with cCHP-PspA induces high levels
of systemic antibodies. To address whether intranasal adminis-
tration of cCHP-PspA induced PspA-specific antibody responses,
we examined the serum titers of PspA-specific antibodies. PspA-
specific IgG responses in the systemic compartment were signifi-
cantly higher in mice immunized with intranasal cCHP-PspA
than in those given PspA only (Fig. 5A). Unlike the predominant
IgG response, IgM and IgA titers in the serum samples were very
low (Fig. 5A).
Intranasal immunization with cCHP-PspA induced primarily
IgG1 antibodies, followed by IgG2b antibodies (Fig. 5B). This pat-
tern indicated skewing toward a Th2-type response and was con-
sistent with the cytokine profiles of the culture supernatants from
antigen-stimulated CD4 T cells prepared from the same mice
(Fig. 4B and C).
Intranasal vaccination with cCHP-PspA induces high levels
of mucosal antigen-specific sIgA antibodies. We next examined
whether vaccinated mice also produced mucosal antigen-specific
Ig responses. Intranasal vaccination with cCHP-PspA induced
FIG 2 In vivo imaging revealed no sign of pneumococcal infection in the lungs of mice immunized intranasally with cCHP-PspA; these mice also showed
enhanced bacterial clearance from the BALF and lung. Images (A) and average photon counts (B) show bioluminescence due to S. pneumoniae Xen10 in each
group of mice infected intranasally with S. pneumoniae Xen10 (2  105 CFU/mouse) and imaged 24, 48, and 72 h after infection. (C and D) One week after the
final immunization, mice were challenged with a sublethal dose (2  104 CFU/mouse) of S. pneumoniae Xen10. BALF and lung tissues were collected, and the
numbers of S. pneumoniae Xen10 organisms 3 and 24 h after challenge were determined. Data are representative of three independent experiments, and each
group consisted of 5 mice. *, P  0.05; **, P  0.01; ***, P  0.001. Abbreviations: BALF, bronchoalveolar lavage fluid; cCHP, cationic cholesteryl-group-bearing
pullulan; PspA, pneumococcal surface protein A.
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PspA-specific mucosal IgA antibodies in the nasal secretions
(Fig. 6A). In addition, BALF samples from mice intranasally vac-
cinated with cCHP-PspA contained PspA-specific IgA antibodies
(Fig. 6B), and PspA-specific IgG antibodies were detected at high
titers in both the NWs and BALF of mice intranasally immunized
with cCHP-PspA (Fig. 6C and D). The nasal and BALF antigen-
specific IgGs induced by intranasal immunization with cCHP-
PspA were primarily of the IgG1 and IgG2b subclasses (Fig. 6E and
F), similar to the Ig responses in the systemic compartment
(Fig. 5B). Taken together, these results further support the benefit
of cCHP-based nanogel as an effective nasal vaccine delivery ve-
hicle for the induction of PspA-specific systemic and mucosal an-
tibody responses against S. pneumoniae.
cCHP delivers PspA to dendritic cells (DCs) without CNS
accumulation of PspA. The potential for antigen deposition and
accumulation in the CNS through the olfactory fossa is one of the
great concerns surrounding the use of nasal vaccines (33, 34, 50).
To address this important concern, we instilled 111In-labeled PspA
alone or in complex with cCHP into the nasal cavities of mice.
Beginning 6 h after administration, the nasal passages of mice
treated with 111In-labeled cCHP-PspA had higher SUVs than did
those of mice treated with 111In-labeled PspA alone, but there was
no accumulation of 111In-labeled PspA in the olfactory bulbs or
brain throughout the 48-h observation period (Fig. 7A).
The cCHP vaccine delivery system enabled prolonged antigen
exposure at the nasal epithelium, allowing continuous antigen
FIG 3 Intranasal vaccination with cCHP-PspA reduced bacterial colonization
of the nasal cavity. One week after the final immunization, mice were chal-
lenged with a sublethal dose (2  104 CFU/mouse) of Streptococcus pneu-
moniae Xen10. Nasal washes and tissues were collected, and the numbers of S.
pneumoniae Xen10 3 days after infection were determined. Data are represen-
tative of three independent experiments, and each group consisted of 5 mice. *,
P  0.05; **, P  0.01. Abbreviations: cCHP, cationic cholesteryl group-bear-
ing pullulan; PspA, pneumococcal surface protein A.
FIG 4 CD4 T cells from cCHP-PspA-immunized mice produce Th17- and
Th2-type immune responses. Cytokines produced by CD4 T cells isolated
from the spleens, cervical lymph nodes, and nasal passages of mice immunized
with cCHP-PspA, PspA alone, or PBS only were analyzed. Data are represen-
tative of five independent experiments, and each group consisted of 5 mice.
Abbreviations: cCHP, cationic cholesteryl-group-bearing pullulan; CLN, cer-
vical lymph node; IFN-, gamma interferon; IL, interleukin; PspA, pneumo-
coccal surface protein A.
Nanogel-Based PspA Nasal Pneumococcal Vaccine
May 2013 Volume 81 Number 5 iai.asm.org 1629







uptake by nasal DCs located in the epithelial layer and lamina
propria of the nasal passages for the initiation of antigen-specific
immune responses. Whereas 17.8% of the DCs located in the nasal
passages had taken up PspA in the mice intranasally immunized
with cCHP-PspA, only 0.7% of nasal DCs contained PspA antigen
in mice that had been immunized intranasally with PspA alone
(Fig. 7B). These results further support the concept that the
cCHP-PspA vaccine formulation is an attractive inhalant delivery
vehicle that effectively delivers and sustains antigen at the nasal
epithelium for continuous antigen uptake by DCs without antigen
deposition in the CNS.
DISCUSSION
We showed that cCHP-PspA-vaccinated mice survived a lethal
challenge with S. pneumoniae (Fig. 1; see Fig. S4 in the supplemen-
tal material), whereas mice vaccinated with cCHP complexed with
an irrelevant antigen (BoHc/A) did not (see Fig. S3 and S4). Im-
portantly, compared with those of mice inoculated with control
constructs, the respiratory tracts of mice immunized with intra-
nasal cCHP-PspA had less colonization and invasion by pneumo-
coccal organisms (Fig. 2 and 3). Intranasal administration of
cCHP-PspA resulted in enhanced PspA-specific Th17 responses
(Fig. 4A) and mucosal IgA and systemic IgG antibody responses
(Fig. 5 and 6), all of which are involved in establishing protective
immunity against pneumococci (10, 28–30). To our knowledge,
the current study is the first to show the efficacy of a nasal vaccine
not only for inducing protective immune responses but also for
preventing nasal colonization by use of a single protein antigen
(PspA) without adding any biologically active adjuvant.
The precise mechanisms underlying the efficacy of cCHP-
PspA as a nasal vaccine against S. pneumoniae lung infection re-
main to be elucidated. However, we speculate that serum and
BALF IgGs, the main isotype of antibody induced by the cCHP-
PspA nasal vaccine in the lower respiratory compartment (Fig. 5A
and 6D), play key roles in survival against lethal challenge with S.
pneumoniae, given that antibody titers of PspA-specific IgA in the
BALF were low (Fig. 6B) and therefore might contribute only
minimally to protection against invasive diseases. This hypothesis
is supported by the results of a previous study (28) in which
IgA	/	 mice immunized with intranasal PspA-adjuvant (i.e., a
plasmid expressing Flt3 ligand cDNA) mounted a protective im-
mune response against lethal challenge with S. pneumoniae. Our
current study shows that the cCHP-PspA nasal vaccine effectively
induced antigen-specific sIgA antibodies in the upper airways
(Fig. 6A). Immunization of IgA	/	 mice with intranasal PspA-
adjuvant did not prevent pneumococcal colonization of the nasal
cavity (28). In light of the findings of the previous study (28) and
our current one, serum antigen-specific IgG antibodies are crucial
to preventing invasive disease associated with clinical signs,
whereas antigen-specific sIgA antibodies are essential for prevent-
ing colonization of the upper respiratory tract by S. pneumoniae.
In addition to the essential role of sIgA in protection from
nasopharyngeal colonization by pneumococci, IL-17A-producing
CD4 T cells play an important role in preventing pneumococcal
nasal colonization in mice immunized with intranasal pneumo-
coccal whole-cell antigen (29, 30). Recent studies have found that
IL-17 promotes multiple aspects of humoral immunity by en-
hancing B cell proliferation and isotype switching (51), B cell re-
cruitment to the respiratory mucosa, and expression of the poly-
meric immunoglobulin receptor on the airway epithelium (52). In
the current study, we found that intranasal immunization with
cCHP-PspA generated Th17 cells in the nasal passages, draining
lymph nodes, and systemic compartment (Fig. 4A). Therefore,
our findings suggest that intranasal immunization with cCHP-
PspA induces both humoral and cellular immune responses,
which are required for protective immunity against pneumococ-
cal colonization and invasive disease. In addition to their essential
role in antipneumococcal immunity (29, 30), Th17 responses are
a hallmark of autoimmunity (53). Therefore, future studies
should carefully examine whether the Th17 responses induced by
intranasal immunization with cCHP-PspA are associated with any
adverse effects.
As one might expect, the protective immunity induced by nasal
cCHP-PspA was not observed when an irrelevant antigen,
BoHc/A, was incorporated into cCHP (cCHP-BoHc/A) (35) and
used as a nasal vaccine (see Fig. S3 and S4 in the supplemental
material). Moreover, mice immunized intranasally with cCHP-
PspA (PspA of clades 1 and 2) were protected against challenge
with pneumococcal strain 3JYP3670, which expresses PspA of
clade 4 (10), whereas mice immunized with cCHP-BoHc/A, PspA
FIG 5 Intranasal vaccination with cCHP-PspA induced high levels of systemic
antibodies. The data show the PspA-specific serum IgG level (A) and subclass
analysis for IgG1, IgG2a, IgG2b, and IgG3 (B) for each immunized group
(cCHP-PspA, PspA alone, or PBS only). Titers of PspA-specific IgG in sera
were measured on day 7 after final immunization. Data are representative of
three independent experiments, and each group consisted of 5 mice. N.D., not
detected by ELISA with samples diluted 1:32. ***, P  0.001. Abbreviations:
cCHP, cationic cholesteryl group-bearing pullulan; Ig, immunoglobulin;
PspA, pneumococcal surface protein A.
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alone, or PBS were not (see Fig. S4). These findings highlight the
potential advantage of nasal vaccination of cCHP-PspA in induc-
ing antigen-specific protective immunity with subtype cross-reac-
tivity.
Note that cCHP lacks any biologically active adjuvant effect
because it cannot activate immune cells by itself (35). The nanogel
formulation had no effect on the expression of costimulatory mol-
ecules on nasal DCs (see Fig. S5 in the supplemental material),
which are supposed to already express high steady-state levels of
costimulatory molecules in the mucosal environment in response
to numerous inhaled antigens. Our current and previous studies
have shown that antigens are released from the nanogel and are
taken up efficiently by DCs in the nasal mucosa (Fig. 7B) (35).
These studies suggest that cCHP nanogel is an effective carrier that
has strong chaperone-like activity, enabling the delivery of PspA
across the nasal mucosal epithelial cell layer for subsequent uptake
by DCs and initiation of antigen-specific immune responses.
In summary, this study introduced a promising nanometer-
FIG 6 Intranasal vaccination with cCHP-PspA induced strong PspA-specific secretory IgA and IgG responses. Titers of nasal (A and C) and bronchial (B and D)
IgA and IgG induced by intranasal immunization with PspA alone or PspA mixed with cCHP are shown. Titers of PspA-specific IgA and IgG in nasal washes and
BALFs were measured on day 7 after final immunization. Intranasal cCHP-PspA vaccination induced high levels of IgG1 and IgG2b in mucosal secretions of the
upper (E) and lower (F) airways. Data are representative of five independent experiments, and each group consisted of 5 mice. N.D., not detected in undiluted
samples. ***, P  0.001. Abbreviations: BALF, bronchoalveolar lavage fluid; cCHP, cationic cholesteryl-group-bearing pullulan; Ig, immunoglobulin; PspA,
pneumococcal surface protein A.
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FIG 7 Intranasal vaccination with cCHP-PspA induced no accumulation of PspA in the central nervous system (A) but enhanced the efficiency of uptake of PspA
by dendritic cells in the nasal passages (B). (A) 111In-labeled PspA was administered intranasally with or without cCHP nanogel, and the radioisotope counts
(SUVs) in the nasal passages, olfactory bulbs, and brain were estimated 10 min and 1, 6, 12, 24, and 48 h after instillation. (B) Dendritic cells in the nasal passages
of mice immunized intranasally with cCHP-PspA, PspA alone, or PBS were analyzed by flow cytometry 6 h after immunization. Data are representative of three
independent experiments, and each group consisted of 5 mice. *, P  0.05; ***, P  0.001. Abbreviations: cCHP, cationic cholesteryl group-bearing pullulan;
PspA, pneumococcal surface protein A.
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sized carrier-based pneumococcal nasal vaccine that incorporates
cCHP nanogel and the pneumococcal serotype-independent pro-
tein antigen PspA. The antigen-specific immune responses in-
duced by this vaccine effectively protected mice against the respi-
ratory pathogen S. pneumoniae. Our results confirmed that cCHP
nanogel is a promising candidate carrier of a protein antigen for a
mucosal vaccine that induces humoral and cellular immune re-
sponses against PspA to combat colonization and invasion of the
airways by respiratory pathogens.
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